Pharmaceuticals

ARS Pharmaceuticals' needle-free allergy spray, neffy, faces a major setback with commercial insurers, forcing a strategic pivot toward fiscal discipline.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.

A small biotech reports its novel curcumin gel eases sickle cell pain. But its strategy of pre-approval access via pharmacies is a high-stakes economic gamble.

Kadima Neuropsychiatry sues NRx Pharma, alleging deceit in a failed acquisition. The case reveals the high stakes of corporate integrity and financial truth.

The $2B market for chronic hives is exploding, with new drugs from Sanofi, Celldex, and Novartis creating a seismic shift for patients and investors.

A new partnership aims to leverage corporate science and community trust to reverse declining cancer screenings. But can this model truly bridge the gap?

A landmark deal brings VIZZ, a once-daily presbyopia treatment, to Australia and New Zealand, promising millions a life with less reliance on reading glasses.

A new RNA therapy for obesity is advancing in trials. It promises to reduce harmful visceral fat, preserve muscle, and may only require a twice-yearly dose.

Imbria's ninerafaxstat gains FDA Orphan Drug status for nHCM, a rare heart condition. This strategic win pits its unique metabolic approach against rivals.

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

Heparin, a trusted blood thinner, can trigger a fatal immune reaction. A small biotech's novel drug is now taking the global stage with a targeted solution.

As McKesson prepares its August 5th earnings, all eyes are on its strategic overhaul. Will bold moves in oncology and tech deliver on profit promises?

Novartis is betting nearly $2 billion on Antares Therapeutics' novel platform to conquer historically 'undruggable' cancer targets, a move that could redefine oncology.

Ollin Biosciences secured $330M to challenge giants like Roche and Regeneron. Their next-gen antibody shows early promise in treating vision loss.

An alliance of biopharma innovators is set to discuss a critical hurdle in medicine: delivering RNA therapies to tissues beyond the liver, a key to unlocking new treatments.

BOTOX® Cosmetic is investing millions in women entrepreneurs. Is it smart philanthropy, or a brilliant new blueprint for brand building and corporate strategy?

A new $5M partnership promises better patient support. We analyze the model, the money, and the ethical tightrope of pharma-nonprofit collaborations.

As Julie Kim becomes Takeda's new CEO, she inherits a robust pipeline and a fortified board, signaling a strategic shift toward executional excellence.

A massive $115M funding round fuels UK biotech RQ Bio's quest to replace the annual flu shot for the vulnerable with a single, season-long antibody treatment.